View in EDS

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Saved in:
Bibliographic Details
Title: Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.
Authors: Ozer BH; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Cohen AL; Division of Oncology, Huntsman Cancer Institute, Salt Lake City, Utah, USA., Colman H; Department of Neurosurgery, Huntsman Cancer Institute, Salt Lake City, Utah, USA., Penas-Prado M; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., de Groot J; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Loghin ME; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pan E; Department of Neurology and Neurotherapeutics, Division of Hematology-Oncology, University of Texas Southwestern, Dallas, Texas, USA., Raizer JJ; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Kumthekar P; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Fink KL; Department of Neurology/Neuro-Oncology, Baylor University Medical Center, Houston, Texas, USA., Walbert T; Department of Neurology and Neurosurgery, Henry Ford Health, Wayne State and Michigan State University, Detroit, Michigan, USA., Merrell RT; Department of Neurology, NorthShore University Health System, Evanston, Illinois, USA., Groves MD; Texas Oncology, Austin Brain Tumor Center, Austin, Texas, USA., Ahluwalia MS; Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA., Wu J; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Burton EC; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Vera E; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Mendoza T; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Grajkowska E; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Wall K; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Reyes J; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Yuan Y; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Armstrong TS; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Gilbert MR; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.
Source: Neuro-oncology advances [Neurooncol Adv] 2026 Jan 23; Vol. 8 (1), pp. vdaf261. Date of Electronic Publication: 2026 Jan 23 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42028236
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ozer+BH%22">Ozer BH</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Cohen+AL%22">Cohen AL</searchLink>; Division of Oncology, Huntsman Cancer Institute, Salt Lake City, Utah, USA.<br /><searchLink fieldCode="AU" term="%22Colman+H%22">Colman H</searchLink>; Department of Neurosurgery, Huntsman Cancer Institute, Salt Lake City, Utah, USA.<br /><searchLink fieldCode="AU" term="%22Penas-Prado+M%22">Penas-Prado M</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22de+Groot+J%22">de Groot J</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Loghin+ME%22">Loghin ME</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Pan+E%22">Pan E</searchLink>; Department of Neurology and Neurotherapeutics, Division of Hematology-Oncology, University of Texas Southwestern, Dallas, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Raizer+JJ%22">Raizer JJ</searchLink>; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Kumthekar+P%22">Kumthekar P</searchLink>; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Fink+KL%22">Fink KL</searchLink>; Department of Neurology/Neuro-Oncology, Baylor University Medical Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Walbert+T%22">Walbert T</searchLink>; Department of Neurology and Neurosurgery, Henry Ford Health, Wayne State and Michigan State University, Detroit, Michigan, USA.<br /><searchLink fieldCode="AU" term="%22Merrell+RT%22">Merrell RT</searchLink>; Department of Neurology, NorthShore University Health System, Evanston, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Groves+MD%22">Groves MD</searchLink>; Texas Oncology, Austin Brain Tumor Center, Austin, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Ahluwalia+MS%22">Ahluwalia MS</searchLink>; Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Wu+J%22">Wu J</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Burton+EC%22">Burton EC</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Vera+E%22">Vera E</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Mendoza+T%22">Mendoza T</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Grajkowska+E%22">Grajkowska E</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Wall+K%22">Wall K</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Reyes+J%22">Reyes J</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Yuan+Y%22">Yuan Y</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Armstrong+TS%22">Armstrong TS</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Gilbert+MR%22">Gilbert MR</searchLink>; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101755003%22">Neuro-oncology advances</searchLink> [Neurooncol Adv] 2026 Jan 23; Vol. 8 (1), pp. vdaf261. <i>Date of Electronic Publication: </i>2026 Jan 23 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101755003 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2632-2498 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226322498%22">26322498 </searchLink><i>NLM ISO Abbreviation: </i>Neurooncol Adv <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42028236
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/noajnl/vdaf261
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: vdaf261
    Titles:
      – TitleFull: Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ozer BH
      – PersonEntity:
          Name:
            NameFull: Cohen AL
      – PersonEntity:
          Name:
            NameFull: Colman H
      – PersonEntity:
          Name:
            NameFull: Penas-Prado M
      – PersonEntity:
          Name:
            NameFull: de Groot J
      – PersonEntity:
          Name:
            NameFull: Loghin ME
      – PersonEntity:
          Name:
            NameFull: Pan E
      – PersonEntity:
          Name:
            NameFull: Raizer JJ
      – PersonEntity:
          Name:
            NameFull: Kumthekar P
      – PersonEntity:
          Name:
            NameFull: Fink KL
      – PersonEntity:
          Name:
            NameFull: Walbert T
      – PersonEntity:
          Name:
            NameFull: Merrell RT
      – PersonEntity:
          Name:
            NameFull: Groves MD
      – PersonEntity:
          Name:
            NameFull: Ahluwalia MS
      – PersonEntity:
          Name:
            NameFull: Wu J
      – PersonEntity:
          Name:
            NameFull: Burton EC
      – PersonEntity:
          Name:
            NameFull: Vera E
      – PersonEntity:
          Name:
            NameFull: Mendoza T
      – PersonEntity:
          Name:
            NameFull: Grajkowska E
      – PersonEntity:
          Name:
            NameFull: Wall K
      – PersonEntity:
          Name:
            NameFull: Reyes J
      – PersonEntity:
          Name:
            NameFull: Yuan Y
      – PersonEntity:
          Name:
            NameFull: Armstrong TS
      – PersonEntity:
          Name:
            NameFull: Gilbert MR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 01
              Text: 2026 Jan 23
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2632-2498
          Numbering:
            – Type: volume
              Value: 8
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Neuro-oncology advances
              Type: main
ResultId 1